SS-31 Cycle Guide

What Is SS-31 and Why Does Dosing Matter?

SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. Getting the dosage right is critical — too little may produce no measurable effect, while excessive amounts increase risk without proportional benefit.

The standard research dosage for SS-31 has been established through preclinical studies and community protocols. This guide covers the evidence-backed dosing range, timing, and cycle structure.

What Is the Recommended SS-31 Dosage?

The most widely used SS-31 dosage is 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV, administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion.

Beginners should start at the lower end of this range and titrate upward only if needed. The half-life of SS-31 is approximately 20-30 minutes, which directly determines how often you need to dose to maintain stable blood levels.

For SS-31 specifically, the 12-48 weeks in clinical trials cycle length is standard. Longer isn't always better — Mitochondrial-targeting tetrapeptide compounds require cycling to maintain receptor sensitivity.

When Should You Dose SS-31?

With a half-life of approximately 20-30 minutes, timing your SS-31 administration affects peak blood levels. Most protocols call for daily subcutaneous or weekly IV infusion.

For peptides administered before bed (common with GH-related compounds), the goal is to amplify the natural nocturnal growth hormone pulse. For healing peptides, proximity to the injury site via local injection can improve outcomes.

How Do You Reconstitute SS-31?

SS-31 typically comes as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water — never saline or sterile water, as BAC water contains 0.9% benzyl alcohol that prevents bacterial growth and extends shelf life to 4-6 weeks.

Use our peptide dosing calculator to determine the exact amount of BAC water to add based on your vial size and desired dose per injection.

How Long Should a SS-31 Cycle Last?

Standard SS-31 cycles run 12-48 weeks in clinical trials. This timeframe is based on the compound's mechanism and the time needed to observe measurable effects.

FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.

What Side Effects Can Affect Dosing?

Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.

If side effects emerge, the first step is typically reducing the dose rather than discontinuing entirely. Most SS-31-related side effects are dose-dependent.

How Does SS-31 Dosing Change When Stacking?

Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.

When stacking, some researchers reduce individual peptide doses by 20-30% since synergistic effects mean full doses of each aren't always necessary.

What Is the Bottom Line on SS-31 Dosing?

Start at 4, dose daily subcutaneous or weekly IV infusion, and run cycles of 12-48 weeks in clinical trials. Monitor your response and adjust within the established range.

Source matters — always use research-grade SS-31 from vendors with third-party COA testing. Underdosed or contaminated products are the most common reason for poor results.

Related Reading

• SS-31 Benefits
• SS-31 Side Effects
• SS-31 Stacking Guide
• SS-31 Cycle Guide
• SS-31 Research
• MOTS-C Complete Guide

Frequently Asked Questions